Literature DB >> 3030151

Prognostic indicators in cystosarcoma phylloides.

J R Hines, T M Murad, J M Beal.   

Abstract

Cystosarcoma phylloides is a breast neoplasm that has a frequently unpredictable clinical course. We made a retrospective study of 25 patients with this disease in an attempt to evaluate the indicators of aggressive behavior. In our series, older patient age, nulliparity, rapid tumor growth, pain, and large size of tumors increased the suspicion of malignancy but were not always reliable indicators of malignancy. Skin ulceration, tumor necrosis, and infiltrating tumor margins were the most ominous characteristics. High-grade tumors, that is, those with increased cellularity, vascularity, mitotic figure, and pleomorphism, often indicated aggressive behavior. Mixed mesenchymal components were sometimes related to a malignant course. We found a 24 percent incidence of associated breast cancer. Carcinoma of the ipsilateral breast was found in four patients and later in the contralateral breast in two patients. Of our 25 patients, 10 (40 percent) had recurrence and 4 (16 percent) died from disease. Recurrences after treatment usually occurred within 3 years. Patients must be followed carefully for local recurrence or metastases, since the clinical course is not predictable. Forty percent of the lesions were diagnosed as being malignant. Local excision was associated with recurrence in six of eight patients and was clearly inadequate treatment. Quadrantectomy was effective for benign peripheral lesions when a generous margin could be obtained. From these data, we believe that mastectomy is indicated in all patients with malignant lesions and in those with large benign lesions.

Entities:  

Mesh:

Year:  1987        PMID: 3030151     DOI: 10.1016/0002-9610(87)90601-5

Source DB:  PubMed          Journal:  Am J Surg        ISSN: 0002-9610            Impact factor:   2.565


  9 in total

Review 1.  Phyllodes tumors of the breast: diagnosis, treatment and prognostic factors related to recurrence.

Authors:  Zhi-Rui Zhou; Chen-Chen Wang; Zhao-Zhi Yang; Xiao-Li Yu; Xiao-Mao Guo
Journal:  J Thorac Dis       Date:  2016-11       Impact factor: 2.895

Review 2.  Phyllodes tumours.

Authors:  S J Parker; S A Harries
Journal:  Postgrad Med J       Date:  2001-07       Impact factor: 2.401

3.  Unexpectedly High Coexistence Rate of In Situ/Invasive Carcinoma In Phyllodes Tumors. 10-Year Retrospective and Review Study.

Authors:  Öykü Dila Gemci; Serdar Altınay; Rümeysa İlbar Tartar; Sina Ferahman
Journal:  Eur J Breast Health       Date:  2022-10-01

4.  An evaluation of the preoperative diagnosis and management of cystosarcoma phyllodes.

Authors:  H C Umpleby; I Moore; G T Royle; P B Guyer; I Taylor
Journal:  Ann R Coll Surg Engl       Date:  1989-09       Impact factor: 1.891

5.  The largest and neglected giant phyllodes tumor of the breast-A case report and literature review.

Authors:  S Islam; J Shah; P Harnarayan; V Naraynsingh
Journal:  Int J Surg Case Rep       Date:  2016-07-22

6.  A Rare Case of Phyllodes Tumor Metastasis to the Stomach Presenting as Anemia.

Authors:  Do Il Choi; Ho Seok Chi; Sang Ho Lee; Youngmee Kwon; Seog Yun Park; Sung Hoon Sim; In Hae Park; Keun Seok Lee
Journal:  Cancer Res Treat       Date:  2016-09-01       Impact factor: 4.679

Review 7.  Primary soft tissue sarcoma of the breast.

Authors:  J C Trent II; R S Benjamin; V Valero
Journal:  Curr Treat Options Oncol       Date:  2001-04

Review 8.  Giant breast tumors: surgical management of phyllodes tumors, potential for reconstructive surgery and a review of literature.

Authors:  Margaret I Liang; Bhuvaneswari Ramaswamy; Cynthia C Patterson; Michael T McKelvey; Gayle Gordillo; Gerard J Nuovo; William E Carson
Journal:  World J Surg Oncol       Date:  2008-11-11       Impact factor: 2.754

9.  Phyllodes tumor of the breast: a retrospective study of the impact of histopathological factors in local recurrence and distant metastasis.

Authors:  Samer Sawalhi; Marwa Al-Shatti
Journal:  Ann Saudi Med       Date:  2013 Mar-Apr       Impact factor: 1.526

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.